gdc
ImmunotherapyLeukemiaLymphomaPersonalized Medicine

Telling Patients About CAR T-Cell Therapy

Nurse Navigator Claire White describes the way she tells her patients what CAR T-cell therapy is and how it works.
Video Library – March 6, 2019
Claire White, BSN, RN, CPHON
The Children's Hospital of Philadelphia, Philadelphia, PA
Nurse Navigator Claire White describes the way she tells her patients what CAR T-cell therapy is and how it works.
Recommended For You
Leukemia
Acalabrutinib-Based Triplet Shows Promise in Frontline CLL Study
The chemotherapy-free combination of venetoclax plus obinutuzumab has shown efficacy and tolerability in older patients with chronic lymphocytic leukemia. Adding acalabrutinib, a new targeted agent, may enhance the clinical benefits of this regimen, according to results of a clinical trial.
Leukemia
New Scoring System Helps Patients with CLL and Their Doctors Know When to Start Treatment
Cancer specialists are now able to use a new scoring system to decide when to start treatment for patients who have been diagnosed with chronic lymphocytic leukemia.
Leukemia
Clinical Trial Will Evaluate Novel 3-Drug Regimen for First-Line Treatment of CLL
Alliance A041702 is a large clinical trial that is exploring whether adding venetoclax to the combination of ibrutinib and obinutuzumab can improve outcomes in patients with chronic lymphocytic leukemia.
Leukemia
Undetectable Minimal Residual Disease Associated with Long-Term Survival in CLL
According to results from a recent study, patients with chronic lymphocytic leukemia are more likely to survive for longer time periods if their posttreatment tests show no evidence of residual disease.
Last modified: March 25, 2019

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country